Review Links Methadone Maintenance to Clinically Relevant QT Risk

A systematic review published Oct. 15 in BMC Pharmacology and Toxicology concluded that methadone maintenance therapy carries a clinically relevant risk of QTc prolongation, the electrical slowing of the heart that can precede dangerous ventricular rhythms. The authors, led by Kamaledin Alaedini Shoormasti, synthesized 25 studies and found the association consistent across them, with the effect appearing to scale with dose and concentrating in particular groups of patients.

Two of those groups are named in the paper's results: female patients, and patients taking other medications alongside methadone, "particularly benzodiazepines." The review also reports that several of the included studies found QTc prolongation at relatively low methadone doses — a finding that cuts against the assumption that cardiac risk belongs only to high-dose patients.

Methadone is one of three medications approved in the United States for opioid use disorder, alongside buprenorphine and naltrexone, and it is dispensed to most patients through federally regulated opioid treatment programs. For people who stabilize on it, the alternative is often untreated opioid use disorder, which carries a far higher immediate risk of death than the cardiac signal described in the review.

How the reviewers assembled the evidence

The team followed PRISMA reporting standards and searched Embase, PubMed and Scopus through 2025. Two reviewers independently selected studies, extracted data and graded reporting quality against the STROBE checklist. Because the included studies varied too much in design and population to pool numerically, the authors used a narrative synthesis rather than a meta-analysis — a methodological choice that shapes what the paper can and cannot claim.

That choice is visible in the results. The review describes a direction of effect and a set of factors that appear to amplify it. It does not produce a single pooled estimate of how much the QTc interval lengthens, or how often a patient on methadone develops a dangerous rhythm.

Where the risk concentrates

Dose is the factor the literature treats most consistently. The review reports a dose-related pattern, which aligns with what regulators have said for years.

The female-sex finding is less familiar and more consequential for screening, because sex is not a modifiable risk factor and does not show up in the routine questions asked at intake. The benzodiazepine finding is different: co-prescribing is a clinical decision, and one that addiction providers make frequently, since anxiety and insomnia are common among people entering treatment.

The review's conclusion ties these threads together, describing methadone maintenance as carrying a clinically relevant risk of QTc prolongation "which may increase susceptibility to ventricular arrhythmias in vulnerable patients," and urging careful cardiac monitoring and individualized risk assessment.

The label has warned about this for two decades

Methadone's prescribing information describes the same hazard in more clinical terms. Cases of QT interval prolongation and torsades de pointes — a specific, potentially fatal ventricular arrhythmia — "have been observed during treatment with methadone," according to the label, and appear "more commonly associated with, but not limited to, higher dose treatment (> 200 mg/day)."

The label adds a detail the review's low-dose finding echoes: while most reported cases involved pain patients on large, multiple daily doses, "cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction." In those lower-dose cases, the label notes, concomitant medications or conditions such as low potassium were often present as contributing factors.

It directs clinicians to monitor patients with risk factors closely — cardiac hypertrophy, diuretic use, low potassium or magnesium, a history of conduction abnormalities, and concurrent use of drugs that affect cardiac conduction — and to evaluate modifiable factors when prolongation appears.

What the review does not settle

The paper is a map of a hazard, not a protocol. It does not recommend a specific electrocardiogram schedule, a QTc threshold at which to change treatment, or a dose ceiling. It cannot say whether the sex difference reflects physiology, body composition, prescribing patterns or something else, because the underlying studies were not built to answer that question.

Nor does it establish incidence. A patient reading the review will not learn his or her own odds, and a program director will not find a benchmark for how many patients at a clinic might be affected. Those numbers exist in individual cohort studies — several of which the review summarizes — but not in a pooled form.

What the paper does do is put the cardiac question back alongside the overdose question for a medication dispensed through a national network of opioid treatment programs. For patients stable on methadone, that means a conversation with a prescriber about baseline and follow-up cardiac monitoring, electrolytes and what else is in the medicine cabinet — not a reason to stop. Abrupt discontinuation of methadone produces withdrawal and returns a person to the illicit supply, which is the outcome medication treatment exists to prevent.